top of page

ADVANCING THE FUTURE OF DRUG DISCOVERY AND HUMAN HEALTH

​

​P4Bios is bridging the gap between complex systems biology and new drug discovery paradigms to address the universal stagnation in drug development. Led by a multidisciplinary team of pioneers in science, finance, and technology, we are redefining the landscape of biomedical innovation. 

Following a successful seed funding round, P4Bios is currently executing a rigorous Proof-of-Concept (POC) phase. This
foundational work is on track for completion in Q3 2026.

 

​

Contact P4BIOS 

  • Facebook
  • Twitter
  • LinkedIn
  • Instagram

Thanks for submitting!

DISCALIMER (1) This website contains forward looking statements, including, without limitation, statements regarding P4Bios’s development plans, strategy, objectives, and anticipated timelines (such as our proof of concept activities and the timing we are currently targeting for their completion). These statements are based on current expectations, estimates, forecasts, and projections, and are not guarantees of future performance. Forward looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including risks related to fundamental scientific and technical feasibility, financing and capital availability, manufacturing and supply, reliance on third parties and collaborators, intellectual property, market acceptance, and the competitive landscape. Actual outcomes may differ materially and timing is subject to change. P4Bios undertakes no obligation to update or revise any forward‑looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law. Readers are cautioned not to place undue reliance on these forward‑looking statements. (2) This website and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy any securities of P4Bios, Inc. Any such offer or solicitation will be made only by means of a confidential Private Placement Memorandum and related subscription documents. (3) Regulatory Notice: These securities have not been registered under the U.S. Securities Act of 1933 or any state securities laws (including Washington or Delaware). They are offered and sold under exemptions from registration for private placements.

P4BIOS

©2025 by P4BIOS. Proudly created with Wix.com

bottom of page